Developing Breakthrough Progenitor Cell and Protein Therapeutics

Company Overview

Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. Stemedica has developed a proprietary manufacturing technology platform that produces allogeneic progenitor cell products with intellectual property protection under a low-oxygen, low-tension environment in a cGMP-compliant manufacturing facility. The company’s lead drug candidate, ischemia-tolerant mesenchymal stem cells, or itMSCs, is an allogeneic progenitor cell therapy currently in clinical development for the treatment of ischemic stroke and Alzheimer’s disease. The company’s second drug candidate, ischemia-tolerant neural progenitor cells, or itNSCs, is an allogeneic cell therapy currently in development for spinal cord injury. In addition, Stemedica is developing progenitor multi-cell therapy (itMSCs and itNSCs) for ischemic stroke and progenitor cell and protein combination therapy for Alzheimer’s disease.



“At Stemedica, we believe that today’s most advanced clinicians and researchers deserve superior progenitor cell products to fuel their work. It is this belief that drives our mission: “To develop and manufacture the best ischemic tolerant allogeneic progenitor cells and protein therapeutics available in the advancement of science and medicine.”
Roger J. Howe, PhD

Board of Directors